Catalent plans to draw on revolver to fund acquisition of Pharmatek

By Angela McDaniels

Tacoma, Wash., Sept. 13 – Catalent, Inc. plans to use borrowings under its revolving credit facility and cash to fund the acquisition of Pharmatek Laboratories, Inc., according to a company news release.

The company expects the all-cash acquisition to close in the next few weeks.

Catalent said it will not disclose the purchase price.

Catalent is a Somerset, N.J.-based provider of delivery technologies and development solutions for drugs, biologics and consumer health products. Pharmatek is a drug development and clinical manufacturing company based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.